NEW YORK and PARIS, Feb. 24,
2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis
(EURONEXT: SAN; NYSE: SNY) today announced that it has completed
the previously announced acquisition of BMP Sunstone Corporation
(NASDAQ: BJGP). At a special meeting of stockholders held today,
BMP Sunstone stockholders approved the adoption of the merger
agreement among BMP Sunstone, sanofi-aventis and Star 2010, Inc., a
wholly owned subsidiary of sanofi-aventis, dated October 28, 2010, as amended on November 22, 2010. Following the special
meeting, the merger was completed.
Pursuant to the merger agreement, BMP Sunstone stockholders will
receive USD 10.00 per share in cash
for each share of common stock they owned immediately prior to the
effective time of the merger. Stockholders of record will receive a
letter of transmittal and instructions on how to surrender their
shares of BMP Sunstone common stock to the paying agent in exchange
for the merger consideration.
With the closing of the merger, BMP Sunstone common stock will
no longer trade on the NASDAQ Global Market following today's
market close and will be delisted.
Morgan, Lewis & Bockius LLP served as counsel to BMP
Sunstone. Stephens Inc. acted as financial advisor to BMP Sunstone.
Shearman & Sterling LLP served as counsel to
sanofi-aventis. Morgan Stanley acted as financial advisor to
sanofi-aventis.
About BMP Sunstone
BMP Sunstone Corporation is a specialty pharmaceutical company
that is building a proprietary portfolio of branded pharmaceutical
and healthcare products in China.
Through Sunstone the Company manufactures leading pediatric and
women's health products sold in pharmacies throughout the country.
The Company also markets a portfolio of products under exclusive
multi-year licenses into China,
primarily focused on women's health and pediatrics, as well as
provides pharmaceutical distribution services through subsidiaries
in Beijing and Shanghai. BMP Sunstone's main office is in
Beijing, with a U.S. office in
Plymouth Meeting, PA.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company,
discovers, develops and distributes therapeutic solutions to
improve the lives of everyone. Sanofi-aventis is listed in
Paris (EURONEXT: SAN) and in
New York (NYSE: SNY). For
more information, please visit www.sanofi-aventis.com.
|
Contacts for
sanofi-aventis:
|
|
|
|
|
|
|
Media Contact:
|
Investor Contact:
|
|
|
Jean-Marc Podvin
|
Sebastien Martel
|
|
|
Tel: +33 1 53 77 44
50
|
Tel: +33 1 53 77 45
45
|
|
|
Email: MR@sanofi-aventis.com
|
Email:
IR@sanofi-aventis.com
|
|
|
|
|
|
Contacts for BMP
Sunstone:
|
|
|
|
|
|
|
Media Contact:
|
Investor Contact:
|
|
|
Fred M. Powell
|
ICR, LLC (Investor
Relations)
|
|
|
Tel: +1-610-940-1675
|
Ashley M. Ammon
|
|
|
Email: fpowell@bmpsunstone.com
|
Tel: +1-646-277-1227
|
|
|
|
SOURCE BMP Sunstone Corporation